Biphenylketones were identified as novel inhibitors of NFκB activation. Structure–activity studies led to the identification of compound 4c, which had good potency against osteoclasts (IC50= 0.8 μM), showed oral activity, and was able to completely prevent inflammation and bone loss in vivo.